N-MOmentum Phase 2/3 trial

Long-term treatment with Uplizna (inebilizumab) was well tolerated and led to sustained disease control for adults with neuromyelitis optica spectrum disorder (NMOSD). That’s according to final data from the open-label extension period of the Phase 2/3 N-MOmentum clinical trial (NCT02200770), top-line data of which supported the therapy’s…

Treatment with Uplizna (inebilizumab-cdon) effectively prevented disease attacks and disability worsening for Asian people with neuromyelitis optica spectrum disorder (NMOSD) in the Phase 2/3 N-MOmentum clinical trial, a new analysis found. “In the Asian [patient] subgroup, the risk of NMOSD attacks was reduced with [Uplizna] versus placebo ……

Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum clinical trial, which tested the approved therapy Uplizna (inebilizumab-cdon), a new study shows. The study, “Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by…

Uplizna (inebilizumab) does not increase the risk of COVID-19 infection or reduce the levels of antibodies produced from prior childhood vaccines among people with neuromyelitis optica spectrum disorder (NMOSD). That’s according to two posterior analyses of data from the Phase 2/3 N-MOmentum clinical trial (NCT02200770) after the…

Among people with neuromyelitis optica spectrum disorder (NMOSD) who started treatment with Uplizna (inebilizumab-cdon) in a clinical trial, an early and strong reduction in B-cell counts was associated with a quicker decline in disease activity. This report comes from an analysis of data from the Phase 2/3…

Uplizna (inebilizumab-cdon) was found effective both at reducing attacks and lessening disability in people with neuromyelitis optica spectrum disorder (NMOSD) living in Europe, according to data from the N-MOmentum Phase 2/3 trial. Nearly 90% of participants given Uplizna remained free from attacks six months after starting the therapy,…

Uplizna (inebilizumab-cdon) works to treat people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether such patients carry genetic variants linked to poor responses to other B-cell depleting therapies, new trial data show. An analysis of N-MOmentum Phase 2/3 data found that the approved therapy was as effective…

Uplizna (inebilizumab-cdon) was just as safe and effective in people with neuromyelitis optica spectrum disorder (NMOSD) treated after only one symptomatic attack as those treated after two or more attacks, according to an analysis of N-MOmentum Phase 2/3 trial data. This sub-analysis had sought to understand how a…

Blood levels of two proteins, GFAP and neurofilament light chain (NfL), may help predict the course of neuromyelitis optica spectrum disorder (NMOSD), according to new research. Findings also suggest that many NMOSD patients have evidence of brain lesions with active inflammation without any associated symptoms, which indicates that disease…

Uplizna (inebilizumab-cdon) effectively reduced the severity of attacks in people with neuromyelitis optica spectrum disorder (NMOSD) who continued to experience attacks after being treated with the therapy during the N-MOmentum Phase 2/3 clinical trial, recent data analysis shows. The data also demonstrated lower levels of key disease-related biomarkers,…